Dupuytren's Contracture News and Research

RSS
Dupuytren's contracture is a condition that impacts the fingers and the hands, causing at least one finger, and possibly several, to bend toward the palm of the hand. Also known as Dupuytren's disease, the condition can affect both hands, including the thumbs.
FDA grants approval to first treatment for rare blood cancer

FDA grants approval to first treatment for rare blood cancer

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

Endo Announces Updated XIAFLEX® Label in Patients with Dupuytren’s Contracture

Endo Announces Updated XIAFLEX® Label in Patients with Dupuytren’s Contracture

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Positive results from XIAFLEX phase IIIb multicord trial for Dupuytren's contracture

Positive results from XIAFLEX phase IIIb multicord trial for Dupuytren's contracture

Health Canada approves XIAFLEX for Dupuytren's contracture

Health Canada approves XIAFLEX for Dupuytren's contracture

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Actelion, Auxilium partner to develop and commercialize XIAFLEX

Actelion, Auxilium partner to develop and commercialize XIAFLEX

Study compares needle fasciotomy and conventional surgery for Dupuytren's contractures

Study compares needle fasciotomy and conventional surgery for Dupuytren's contractures

FzioMed's DYNAVISC adhesion barrier gel receives European CE Mark approval

FzioMed's DYNAVISC adhesion barrier gel receives European CE Mark approval

Auxilium initiates XIAFLEX phase IIa trial in Frozen Shoulder syndrome

Auxilium initiates XIAFLEX phase IIa trial in Frozen Shoulder syndrome

BioSpecifics reports $0.3M net income for third quarter 2011 vs. $0.5M net loss for third quarter 2010

BioSpecifics reports $0.3M net income for third quarter 2011 vs. $0.5M net loss for third quarter 2010

Auxilium reports net revenues of $66.7 million for third quarter 2011

Auxilium reports net revenues of $66.7 million for third quarter 2011

Dosing commences in Auxilium's XIAFLEX phase IIIb trial for Dupuytren's contracture

Dosing commences in Auxilium's XIAFLEX phase IIIb trial for Dupuytren's contracture

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Auxilium second quarter net loss decreases to $5.1 million

Auxilium second quarter net loss decreases to $5.1 million

Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture

Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

BioSpecifics 2010 net loss decreases to $1.5 million

BioSpecifics 2010 net loss decreases to $1.5 million